| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,058,700 | 2 | 3 |
Sells | $99,850,980 | 71 | 97 |
| Hayden Michael R | director | 2 | $1.06M | 0 | $0 | $1.06M |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | 0 | $0 | 2 | $506,963 | $-506,963 |
| PARSHALL B LYNNE | director | 0 | $0 | 2 | $794,955 | $-794,955 |
| BERTHELSEN SPENCER R | director | 0 | $0 | 2 | $1.19M | $-1.19M |
| O'NEIL PATRICK R. | EVP CLO & General Counsel | 0 | $0 | 3 | $1.46M | $-1.46M |
| Birchler Brian | EVP, Corp and Development Ops | 0 | $0 | 4 | $1.83M | $-1.83M |
| WENDER JOSEPH H | director | 0 | $0 | 1 | $2.26M | $-2.26M |
| HERMAN JOAN E | director | 0 | $0 | 1 | $2.31M | $-2.31M |
| Baroldi Joseph | EVP, Chief Business Officer | 0 | $0 | 7 | $2.55M | $-2.55M |
| Geary Richard S | EVP, Chief Development Officer | 0 | $0 | 3 | $2.63M | $-2.63M |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | 0 | $0 | 4 | $3.74M | $-3.74M |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | 0 | $0 | 3 | $4.81M | $-4.81M |
| Diaz Allene M. | director | 0 | $0 | 2 | $5.22M | $-5.22M |
| Swayze Eric | EVP Research | 0 | $0 | 6 | $5.24M | $-5.24M |
| KLEIN JOSEPH III | director | 0 | $0 | 5 | $5.36M | $-5.36M |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | 0 | $0 | 7 | $5.39M | $-5.39M |
| LOSCALZO JOSEPH | director | 0 | $0 | 3 | $5.88M | $-5.88M |
| BENNETT C FRANK | EVP, Chief Scientific Officer | 0 | $0 | 5 | $12.67M | $-12.67M |
| HOUGEN ELIZABETH L | EVP, Finance & CFO | 0 | $0 | 4 | $17.87M | $-17.87M |
| Monia Brett P | Chief Executive Officer | 0 | $0 | 8 | $18.21M | $-18.21M |
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia …
Over the last 12 months, insiders at Ionis Pharmaceuticals, Inc. have bought $1.06M and sold $99.85M worth of Ionis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Ionis Pharmaceuticals, Inc. have bought $858,839 and sold $39.5M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hayden Michael R (director) — $1.06M.
The last purchase of 5,000 shares for transaction amount of $258,000 was made by Hayden Michael R (director) on 2026‑07‑31.
| 2026-10-16 | Sale | Devers Shannon L. | EVP, Chief Human Resources Ofc | 1,357 0.0008% | $43.54 | $59,082 | +2.32% | |
| 2026-10-16 | Sale | Swayze Eric | EVP Research | 53 <0.0001% | $43.54 | $2,308 | +2.32% | |
| 2026-07-31 | Hayden Michael R | director | 5,000 0.003% | $51.60 | $258,000 | -11.49% | ||
| 2026-07-30 | Hayden Michael R | director | 15,000 0.0091% | $53.38 | $800,700 | -13.87% | ||
| 2026-07-07 | Sale | Kordasiewicz Holly B. | EVP, Chief Development Officer | 362 0.0002% | $84.30 | $30,517 | -37.42% | |
| 2026-07-07 | Sale | Diaz Allene M. | director | 10,111 0.0061% | $85.42 | $863,637 | -37.42% | |
| 2026-07-07 | Sale | BENNETT C FRANK | EVP, Chief Scientific Officer | 20,536 0.0122% | $84.95 | $1.74M | -37.42% | |
| 2026-07-01 | Sale | KLEIN JOSEPH III | director | 11,518 0.007% | $79.04 | $910,416 | -31.57% | |
| 2026-06-26 | Sale | Monia Brett P | Chief Executive Officer | 50,000 0.0311% | $80.59 | $4.03M | -33.11% | |
| 2026-06-26 | Sale | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | 26,000 0.0157% | $81.05 | $2.11M | -33.11% | |
| 2026-06-26 | Sale | O'NEIL PATRICK R. | EVP CLO & General Counsel | 3,069 0.0018% | $80.00 | $245,520 | -33.11% | |
| 2026-06-26 | Sale | Baroldi Joseph | EVP, Chief Business Officer | 5,635 0.0034% | $80.16 | $451,699 | -33.11% | |
| 2026-06-25 | Sale | Monia Brett P | Chief Executive Officer | 21,072 0.0128% | $78.49 | $1.65M | -30.57% | |
| 2026-06-25 | Sale | Swayze Eric | EVP Research | 10,602 0.0065% | $79.18 | $839,492 | -30.57% | |
| 2026-06-24 | Sale | Monia Brett P | Chief Executive Officer | 14,565 0.0091% | $78.41 | $1.14M | -28.86% | |
| 2026-06-15 | Sale | BERTHELSEN SPENCER R | director | 8,000 0.0048% | $73.49 | $587,920 | -26.05% | |
| 2026-06-12 | Sale | Kordasiewicz Holly B. | EVP, Chief Development Officer | 60,846 0.0369% | $73.41 | $4.47M | -25.31% | |
| 2026-06-01 | Sale | BERTHELSEN SPENCER R | director | 8,000 0.0049% | $75.67 | $605,360 | -26.33% | |
| 2026-05-14 | Sale | Monia Brett P | Chief Executive Officer | 3,220 0.002% | $78.68 | $253,347 | -25.30% | |
| 2026-05-13 | Sale | Monia Brett P | Chief Executive Officer | 1,316 0.0008% | $78.01 | $102,665 | -27.14% |
| Hayden Michael R | director | 24000 0.0144% | $970,080.00 | 4 | 0 | +68.1% |
| KLEIN JOSEPH III | director | 11014 0.0066% | $445,185.88 | 9 | 41 | +49.6% |
$159,914,414 | 243 | 18.52% | $8.86B | |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 281 | +61.49% | 25M | +14.74% |
| Decreased Positions | 191 | -41.79% | 23M | -13.54% |
| New Positions | 112 | New | 4M | New |
| Sold Out Positions | 45 | Sold Out | 4M | Sold Out |
| Total Postitions | 547 | +19.69% | 171M | +1.21% |
| Fmr Llc | $1.89M | 14.62% | 23.69M | +46,048 | +0.2% | 2025-09-30 |
| Vanguard Group Inc | $1.31M | 10.17% | 16.48M | -233,116 | -1.4% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $1.05M | 8.12% | 13.16M | -3M | -18.02% | 2025-09-30 |
| Capital World Investors | $1.01M | 7.85% | 12.72M | +182,540 | +1.46% | 2025-09-30 |
| Blackrock, Inc. | $832,387.00 | 6.45% | 10.45M | -448,997 | -4.12% | 2025-09-30 |
| Wellington Management Group Llp | $524,931.00 | 4.07% | 6.59M | +243,035 | +3.83% | 2025-09-30 |
| Bellevue Group Ag | $497,495.00 | 3.86% | 6.24M | -2M | -20.48% | 2025-09-30 |
| State Street Corp | $349,644.00 | 2.71% | 4.39M | -141,747 | -3.13% | 2025-09-30 |
| Deep Track Capital, Lp | $303,395.00 | 2.35% | 3.81M | -1M | -22.15% | 2025-09-30 |
| Geode Capital Management, Llc | $244,291.00 | 1.89% | 3.07M | +175,194 | +6.06% | 2025-09-30 |